Ignite Creation Date:
2024-05-06 @ 2:38 AM
Last Modification Date:
2024-10-26 @ 11:21 AM
Study NCT ID:
NCT02091531
Status:
COMPLETED
Last Update Posted:
2019-11-21
First Post:
2014-03-14
Brief Title:
Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer CRPC Patients
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Study Overview
Official Title:
A Phase 2 Study of the Dual mTOR Inhibitor MLN0128 in Patients With Metastatic Castration-Resistant Prostate Cancer CRPC
Status:
COMPLETED
Status Verified Date:
2018-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase II study which will test the study drug MLN0128 in patients with castration resistant prostate cancer who have received chemotherapy in the past Phase II clinical trials test how well an investigational drug works in treating a specific cancer Investigational means that the drug is still being studied and that research doctors are trying to find out more about it MLN0128 is not approved by the FDA
The purpose of this study is to see what effects good and bad the study drug MLN0128 has on the patient and the cancer MLN0128 is a drug that belongs to a class of drugs called mTOR kinase inhibitors A protein called mTOR inside the cells in the body plays a role in controlling how cells grow In some cancer cells mTOR may be over-active This over-activity may cause some cancer cells to grow out of control Research has shown that mTOR inhibitors can block this overactivity and may help stop or slow down the growth of some types of cancer cells
The purpose of this study is to see what effects good and bad the study drug MLN0128 has on the patient and the cancer MLN0128 is a drug that belongs to a class of drugs called mTOR kinase inhibitors A protein called mTOR inside the cells in the body plays a role in controlling how cells grow In some cancer cells mTOR may be over-active This over-activity may cause some cancer cells to grow out of control Research has shown that mTOR inhibitors can block this overactivity and may help stop or slow down the growth of some types of cancer cells
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None